International Journal of Hematology

, Volume 106, Issue 4, pp 533–540 | Cite as

Efficacy of prophylactic irradiation to the contralateral testis for patients with advanced-stage primary testicular lymphoma: an analysis of outcomes at a single institution

  • Ryouji Tokiya
  • Eisaku Yoden
  • Kei Konishi
  • Nobuhiko Kamitani
  • Junichi Hiratsuka
  • Risa Koresawa
  • Tadashi Hirose
  • Fuminori Sano
  • Hirotoshi Tokunaga
  • Toshinori Kondo
  • Hideho Wada
  • Takashi Sugihara
Original Article



Primary testicular lymphoma (PTL) is a rare, extranodal lymphoma that often relapses in the contralateral testis. We evaluated outcomes in patients with any stage of PTL who had received CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) with rituximab chemotherapy and prophylactic radiotherapy to the contralateral testis.


We retrospectively identified 15 patients (median age 66 years; range 39–81) diagnosed with diffuse large B-cell PTL in the period 2000–2014. Characteristics and outcomes of these cases were evaluated.


All patients received initial orchiectomy followed by CHOP with or without rituximab. Thirteen patients received prophylactic irradiation to the contralateral testis. During follow-up (median 67 months; range 8–190), one patient died of PTL, three died of other disease, and nine were free from relapse. For stage I–II disease, 5-year progression-free and overall survival rates were 80 and 100%, respectively. For stage III–IV PTL, 5-year progression-free and overall survival rates were 50 and 72%, respectively. Notably, no patient developed contralateral testicular involvement after prophylactic irradiation.


The observed outcomes suggest that the combination of (i) CHOP plus rituximab and (ii) radiotherapy for local recurrence prophylaxis is promising for both stage I–II and stage III–IV PTL.


Chemotherapy Lymphoma Radiotherapy Rituximab Testis 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29:2766–72.CrossRefPubMedGoogle Scholar
  2. 2.
    Gundrum JD, Mathiason MA, Moore DB, Go RS. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol. 2009;27:5227–32.CrossRefPubMedGoogle Scholar
  3. 3.
    Moller MB, d’Amore F, Christensen BE. Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis. The Danish Lymphoma Study Group, LYFO. Eur J Cancer. 1994;30A:1760–4.CrossRefPubMedGoogle Scholar
  4. 4.
    Shahab N, Doll DC. Testicular lymphoma. Semin Oncol. 1999;26:259–69.PubMedGoogle Scholar
  5. 5.
    Zucca E, Roggero E, Bertoni F, Cavalli F. Primary extranodal non-Hodgkin’s lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol. 1997;8:727–37.CrossRefPubMedGoogle Scholar
  6. 6.
    Crellin AM, Hudson BV, Bennett MH, Harland S, Hudson GV. Non-Hodgkin’s lymphoma of the testis. Radiother Oncol. 1993;27:99–106.CrossRefPubMedGoogle Scholar
  7. 7.
    Fonseca R, Habermann TM, Colgan JP, O’Neill BP, White WL, Witzig TE, et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer. 2000;88:154–61.CrossRefPubMedGoogle Scholar
  8. 8.
    Wang C, Wang H, Wang Q, Shi B. Primary testicular lymphoma: experience with 13 cases and literature review. Int J Hematol. 2013;97:240–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Ahmad SS, Idris SF, Follows GA, Williams MV. Primary testicular lymphoma. Clin Oncol. 2012;24(5):358–65.CrossRefGoogle Scholar
  10. 10.
    Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21:20–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Guideline of a radiation treatment planning. Japanese Society for Therapeutic Radiology and Oncology, version 3. 20 Nov 2012.Google Scholar
  12. 12.
    Deng L, Xu-Monette ZY, Loghavi S, Manyam GC, Xia Y, Visco C, et al. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia. 2016;30:361–72.CrossRefPubMedGoogle Scholar
  13. 13.
    Common toxicity criteria, version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47(1):13–47.CrossRefGoogle Scholar
  14. 14.
    Wittekind C, Henson DE, Hutter RPV, et al. UICC-TNM supplement. A commentary on uniform use (ed2). New York: Wiley-Liss Publishers; 2001. p. 58.Google Scholar
  15. 15.
    The International Non-Hodgkin’s Lymphoma Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–94.CrossRefGoogle Scholar
  16. 16.
    Chesons BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphomas. J Clin Oncol. 2007;25:579–86.CrossRefGoogle Scholar
  17. 17.
    Kahn ST, Flowers C, Lechowicz MJ, Hollenbach K, Johnstone PA. Value of PET restaging after chemotherapy for non-Hodgkin’s lymphoma: implications for consolidation radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:961–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in Cancer Journals. Br J Cancer. 1995;72:511–8.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRefGoogle Scholar
  20. 20.
    Gundrum JD, Mathiason MA, Moore DB, Go RS. Primary testicular diffuse large B-cell lymphoma: a population based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol. 2009;27:5227–32.CrossRefPubMedGoogle Scholar
  21. 21.
    Buskirk SJ, Evans RG, Banks PM, O’Connell MJ, Earle JD. Primary lymphoma of the testis. Int J Radiat Oncol Biol Phys. 1982;8:1699–703.CrossRefPubMedGoogle Scholar
  22. 22.
    Ichikawa K, Noguchi M, Koike M, Aritaka N, Sekiguchi Y, Sunami Y, et al. Rituximab plus a CHOP-like regimen, central nervous system prophylaxis, and contralateral testicular irradiation for localized primary testicular diffuse large B-cell lymphoma lead to prolonged progression-free survival. Int J Hematol. 2014;100:370–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Vitolo U, Ferreri AJ, Zucca E. Primary testicular lymphoma. Crit Rev Oncol Hematol. 2008;65:183–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Hasselblom S, Ridell B, Wedel H, Norrby K, Sender Baum M, Ekman T. Testicular lymphoma, a retrospective, population-based, clinical and immunohistochemical study. Acta Oncol. 2004;43:758–65.CrossRefPubMedGoogle Scholar
  25. 25.
    Avilés A, Neri N, Huerta-Guzmán J, Pérez F, Fernández R. Testicular lymphoma: organ-specific treatment did not improve outcome. Oncology. 2004;67:211–4.CrossRefPubMedGoogle Scholar
  26. 26.
    Cao B, Ji DM, Zhou XY, Zhao TP, Guo Y, Wang ZH, et al. A clinical analysis of primary testicular diffuse large B-cell lymphoma in China. Hematology. 2011;16:291–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Aviles A, Nambo MJ, Cleto S, Neri N, Huerta-Guzmán J. Rituximab and dose-dense chemotherapy in primary testicular lymphoma. Clin Lymphoma Myeloma. 2009;9:386–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Mazloom A, Fowler N, Medeiros LJ, Iyengar P, Horace P, Dabaja BS. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M.D. Anderson Cancer Center experience. Leuk Lymphoma. 2010;51:1217–24.CrossRefPubMedGoogle Scholar
  29. 29.
    Cheah CY, Wirth A, Seymour JF. Primary testicular lymphoma. Blood. 2014;123(4):486–93.CrossRefPubMedGoogle Scholar
  30. 30.
    Visco C, Medeiros LJ, Mesina OM, Rodriguez MA, Hagemeister FB, McLaughlin P, et al. Non-Hodgikin’s lymphoma affecting the testis: Is it curable with doxorubicin-based therapy? Clin Lymphoma. 2000;2:40–6.CrossRefGoogle Scholar
  31. 31.
    Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82 (epub 22 Sep 2003).CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  • Ryouji Tokiya
    • 1
  • Eisaku Yoden
    • 1
  • Kei Konishi
    • 1
  • Nobuhiko Kamitani
    • 1
  • Junichi Hiratsuka
    • 1
  • Risa Koresawa
    • 2
  • Tadashi Hirose
    • 2
  • Fuminori Sano
    • 2
  • Hirotoshi Tokunaga
    • 2
  • Toshinori Kondo
    • 2
  • Hideho Wada
    • 2
  • Takashi Sugihara
    • 2
  1. 1.Department of Radiation OncologyKawasaki Medical SchoolKurashikiJapan
  2. 2.Division of Hematology, Department of MedicineKawasaki Medical SchoolKurashikiJapan

Personalised recommendations